Login
Navigate Fool.com
Will BTX beat
the market?

BioTime, Inc. (NYSEMKT: BTX)

Community Rating: 1 Star: Ominous

2.68 0.07 (2.68%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $2.59
Previous Close $2.61
Daily Range $2.59 - $2.77
52-Week Range $2.21 - $4.18
Market Cap $193.4M
P/E Ratio -3.26
Dividend (Yield) $0.00 (0.0%)
Volume 184,651
Average Daily Volume 235,558
Current FY EPS $0.00

How do you think BTX
will perform against the market?

Top BTX Bull/Bear Pitches

 

BenLevin (16.3)
Submitted December 20, 2012

Like all early-stage biotechs, BioTime's success relies not on its ability to develop novel treatments, but to get them through clinical trial and regulatory testing. BTX isn't setup for that - so my … More

0 Replies Reply Report this Post
 

TMFBiologyFool (< 20)
Submitted May 5, 2011

<a href="http://www.fool.com/investing/general/2011/05/05/the-bearish-case-for-biotime.aspx">http://www.fool.com/investing/general/2011/05/05/the-bearish-case-for-biotime.aspx</a>

0 Replies Reply Report this Post

News & Commentary

Is Geron Finally Onto Something?

Here's why biotech Geron is a prime buyout target.

Sector Update: Health Care Stocks Inching Higher Late; BioTime Climbs Over 9% After Landing 14 New P

Sector Update: Health Care Stocks Inching Higher Late; BioTime Climbs Over 9% After Landing 14 New Patents

Sector Update: Health Care

Stocks: Insiders Buy at Titan International, Cytokinetics, and BioTime

Plus, a purchase at Clearfield.

Insiders Buy Shares at BioTime, TechTarget, and Accelrys

OFG Bancorp also sees a purchase.

3 Reasons Behind Geron's Rebound

Let’s take a look at three reasons Geron bounced back more than 200% in 2013, and how its industry peers -- Celgene, Novartis, and Incyte -- have been affected.

2 Reasons Behind Geron's Rebound

Why has Geron soared 200% in 2013? Let's look at this biotech's performance and its future.

BioTime’s Subsidiary OncoCyte Corporation and The Wistar Institute To Collaboratively Develop Cancer

BioTime Announces Additional Products in Development Based on HyStem® Technology

Asterias Biotherapeutics, Inc., a Subsidiary of BioTime, Inc., Acquires Geron’s Embryonic Stem Cell

See More BTX News...

Sector

Healthcare

Industry

Drugs

BioTime, Inc. (BTX) Description

BioTime Inc. is engaged in the business of developing blood plasma volume expanders and related products and stem cell related products and technology for diagnostic therapeutic and research use. Website: http://www.biotimeinc.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks